Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.
作者信息
Gautret Philippe, Hoang Van Thuan, Lagier Jean-Christophe, Raoult Didier
机构信息
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France; Thai Binh University of Medicine and Pharmacy, Thai Binh, Vietnam.
出版信息
Int J Antimicrob Agents. 2021 Jan;57(1):106239. doi: 10.1016/j.ijantimicag.2020.106239.
Abstract
摘要
相似文献
1
Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.羟氯喹和阿奇霉素治疗COVID-19的效果：一项开放标签非随机临床试验的结果，意向性分析及临床结局的更新
Int J Antimicrob Agents. 2021 Jan;57(1):106239. doi: 10.1016/j.ijantimicag.2020.106239.
2
Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19.用于2019冠状病毒病诊断的严重急性呼吸综合征冠状病毒2聚合酶链反应结果解读
Int J Antimicrob Agents. 2021 Jan;57(1):106238. doi: 10.1016/j.ijantimicag.2020.106238.
3
Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.羟氯喹和阿奇霉素对新型冠状病毒肺炎患者严重急性呼吸综合征冠状病毒2清除率的影响：一项荟萃分析
Int J Antimicrob Agents. 2021 Jan;57(1):106240. doi: 10.1016/j.ijantimicag.2020.106240.
4
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.羟氯喹和阿奇霉素用于治疗新型冠状病毒肺炎：重新审视一项开放标签非随机临床试验的结果
Int J Antimicrob Agents. 2021 Jan;57(1):106243. doi: 10.1016/j.ijantimicag.2020.106243.
5
Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.羟氯喹啉和阿奇霉素治疗新型冠状病毒肺炎的临床疗效及安全性概况
Int J Antimicrob Agents. 2021 Jan;57(1):106242. doi: 10.1016/j.ijantimicag.2020.106242.
6
Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.羟氯喹治疗新型冠状病毒肺炎的疗效评估：一项开放标签非随机临床试验的二次分析
Int J Antimicrob Agents. 2021 Jan;57(1):106172. doi: 10.1016/j.ijantimicag.2020.106172.
7
Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".关注“羟氯喹和阿奇霉素治疗新型冠状病毒肺炎：一项开放标签非随机临床试验的结果”的临床结局。
Int J Antimicrob Agents. 2021 Jan;57(1):106175. doi: 10.1016/j.ijantimicag.2020.106175.
8
Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".致编辑的信：关于“羟氯喹和阿奇霉素作为治疗新型冠状病毒肺炎的药物：一项开放标签非随机临床试验的结果”
Int J Antimicrob Agents. 2021 Jan;57(1):106171. doi: 10.1016/j.ijantimicag.2020.106171.
9
Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.参考研究：《羟氯喹和阿奇霉素治疗新型冠状病毒肺炎：一项开放标签非随机临床试验的结果》
Int J Antimicrob Agents. 2021 Jan;57(1):106176. doi: 10.1016/j.ijantimicag.2020.106176.
10
Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.羟氯喹和阿奇霉素对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒载量的影响尚不确定。
Int J Antimicrob Agents. 2021 Jan;57(1):106169. doi: 10.1016/j.ijantimicag.2020.106169.
引用本文的文献
1
Antibiotics Use in COVID-19 Patients: A Systematic Literature Review.COVID-19患者的抗生素使用：一项系统文献综述
J Clin Med. 2022 Dec 4;11(23):7207. doi: 10.3390/jcm11237207.
2
A Review Pertaining to SARS-CoV-2 and Autoimmune Diseases: What Is the Connection?关于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）与自身免疫性疾病的综述：有何关联？
Life (Basel). 2022 Nov 18;12(11):1918. doi: 10.3390/life12111918.
3
SHEA statement on antibiotic stewardship in hospitals during public health emergencies.医疗保健流行病学学会关于公共卫生紧急情况期间医院抗生素管理的声明。
Infect Control Hosp Epidemiol. 2022 Nov;43(11):1541-1552. doi: 10.1017/ice.2022.194. Epub 2022 Sep 14.
4
WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales.世卫组织 COVID-19 等级量表和炎症风险类别。严重程度量表的比较研究。
J Gen Intern Med. 2022 Jun;37(8):1980-1987. doi: 10.1007/s11606-022-07511-7. Epub 2022 Apr 8.
5
Population Pharmacokinetics of Hydroxychloroquine and 3 Metabolites in COVID-19 Patients and Pharmacokinetic/Pharmacodynamic Application.羟氯喹及其3种代谢产物在新冠肺炎患者中的群体药代动力学及药代动力学/药效学应用
Pharmaceuticals (Basel). 2022 Feb 21;15(2):256. doi: 10.3390/ph15020256.
6
A Peek into Pandora's Box: COVID-19 and Neurodegeneration.窥探潘多拉魔盒：新冠病毒与神经退行性变
Brain Sci. 2022 Jan 30;12(2):190. doi: 10.3390/brainsci12020190.
7
Efficacy of chloroquine and hydroxychloroquine for the treatment of hospitalized COVID-19 patients: a meta-analysis.氯喹和羟氯喹治疗住院COVID-19患者的疗效：一项荟萃分析。
Future Virol. 2021 Nov. doi: 10.2217/fvl-2021-0119. Epub 2021 Dec 3.
8
The immunomodulatory effects of macrolide antibiotics in respiratory disease.大环内酯类抗生素在呼吸疾病中的免疫调节作用。
Pulm Pharmacol Ther. 2021 Dec;71:102095. doi: 10.1016/j.pupt.2021.102095. Epub 2021 Nov 3.
9
A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?短焦点：阿奇霉素治疗呼吸道病毒感染 COVID-19：有效还是无效？
Immunol Res. 2022 Feb;70(1):129-133. doi: 10.1007/s12026-021-09244-x. Epub 2021 Nov 5.
10
The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers.基于炎症标志物的 COVID-19 中皮质类固醇或托珠单抗的使用。
J Gen Intern Med. 2022 Jan;37(1):168-175. doi: 10.1007/s11606-021-07146-0. Epub 2021 Oct 18.
本文引用的文献
1
Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".致编辑的信：关于“羟氯喹和阿奇霉素作为治疗新型冠状病毒肺炎的药物：一项开放标签非随机临床试验的结果”
Int J Antimicrob Agents. 2021 Jan;57(1):106171. doi: 10.1016/j.ijantimicag.2020.106171.
2
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis.法国马赛接受羟氯喹/阿奇霉素和其他方案治疗的 3737 例 COVID-19 患者的结局：一项回顾性分析。
Travel Med Infect Dis. 2020 Jul-Aug;36:101791. doi: 10.1016/j.tmaid.2020.101791. Epub 2020 Jun 25.
3
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
4
Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units-the experience in Sichuan Province, China.2019 - 2020年疫情期间的新型冠状病毒感染：重症监护病房的准备——中国四川省的经验
Intensive Care Med. 2020 Feb;46(2):357-360. doi: 10.1007/s00134-020-05954-2. Epub 2020 Feb 5.
Zotero 插件